Novo Nordisk wins FDA green light for 'holy grail' diabetes drug Rybelsus
admin 20th September 2019 Uncategorised 0Novo Nordisk’s Rybelsus—or, as industry watchers know it, oral semaglutide—snared its FDA nod Friday to control blood sugar in Type 2 diabetes patients. And with the drug’s stellar data and head-to-head study wins against top products in the field, the green light is expected to majorly shake things up.
More: Novo Nordisk wins FDA green light for 'holy grail' diabetes drug Rybelsus
Source: fierce